Carnitin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carnitin

What Type of Medicine is Carnitin (Levocarnitine)?

The medicine Carnitin is a pharmaceutical product containing the active substance Levocarnitine. It is classified as a metabolic and endocrine agent used to regulate amino acid metabolism. This drug class is specifically intended to restore or support the body's internal processes for efficient cellular energy utilization.

Levocarnitine (L-carnitine) itself is a naturally occurring amino acid derivative—a conditionally essential compound synthesized in the human body. Pharmacologically, it is a single-component product typically reserved for prescription use. This ensures a verified, pure dose of the active substance required for therapeutic effect, which distinguishes it from general nutritional supplements.

Composition, Form, and Natural Origin

The drug is supplied as a sterile solution for injection for intravenous administration, or as an oral solution and tablets for ingestion. Levocarnitine is the only biologically active isomer required by the body, serving as a vital quaternary ammonium compound. This specificity is crucial, as the inactive D-carnitine isomer can potentially interfere with the essential L-form's action; this is a key chemical distinction regarding its biological activity.

The General Purpose of Carnitine Replacement Therapy

The overarching purpose of administering Carnitin is to conduct carnitine replacement therapy, correcting a physiological deficit of this critical substance. This therapeutic strategy supports the body's energy production pathways: L-carnitine functions as an essential shuttle system that transports long-chain fatty acids into the mitochondrial matrix where they are broken down for energy.

This role in metabolic processes is central to treating patients with primary or secondary carnitine deficiency who cannot produce sufficient amounts of the compound naturally. By replacing the deficient Levocarnitine, the drug helps restore metabolic efficiency, supporting energy production and the removal of metabolic byproducts.

What side effects are possible with Carnitin?

Possible Side Effects and Safety Information

The safety profile of levocarnitine is officially categorized based on the organ systems affected, frequency of occurrence, and specific patient populations, as documented in regulatory labeling.

Official Adverse Reactions and Classifications

Adverse reactions reported in official documents generally involve the Gastrointestinal System (e.g., nausea, vomiting, abdominal cramps, diarrhea) and are often described as mild or transient. The regulatory documents note that these effects, along with a drug-related Body odor, may be associated with long-term use of the oral solution and may diminish upon reducing the dosage.

Certain effects are classified by the EMA as Very Rare, including gastrointestinal symptoms. Effects involving the Nervous System include the reporting of seizures and an increase in seizure frequency and/or severity in individuals with pre-existing seizure activity.

Serious Adverse Reactions

The most serious adverse reactions documented in regulatory sources are related to Hypersensitivity Reactions. These include rash and facial edema with oral administration, and more severe reactions such as anaphylaxis, laryngeal edema, and bronchospasm reported primarily with the intravenous form, particularly in patients with end-stage renal disease (ESRD) undergoing dialysis.

Population-Specific Safety Considerations

A critical safety consideration applies to patients with severely compromised renal function or ESRD. Chronic, high oral doses in this population may lead to the accumulation of metabolites (trimethylamine, TMA, and its N-oxide, TMAO), a potential constraint noted in official labeling. Additionally, co-administration with coumarinic anticoagulants (e.g., warfarin) has been documented to be associated with an increase in the International Normalized Ratio (INR), a finding that may require specific observation.

Overdose and Emergency Response

Documented Overdose Manifestations

Regulatory documents define the overdose profile by a low acute toxicity risk, confirming that there have been no reports of toxicity from acute Levocarnitine overdosage. The primary clinical manifestation of large-dose exposure is typically restricted to the gastrointestinal system, presenting as diarrhea. Other dose-dependent effects that may be observed include mild gastrointestinal complaints, such as transient nausea and vomiting.


Emergency Response and Management

Official guidance mandates that a poison control center or emergency room be contacted immediately in all cases of suspected overdose, even when symptoms are absent. Overdosage should be treated with supportive care. The prescribing information confirms that Levocarnitine is easily removed from plasma by dialysis, which is the defined procedural measure for systemic clearance. No specific antidote is known.


Population-Specific Overdose Considerations

A specific regulatory constraint exists for patients with severely compromised renal function or those on dialysis. Chronic oral administration of high doses in this population poses a risk for the accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO). This risk informs the specific monitoring required for renally impaired patients receiving high-dose regimens.

Therapeutic Uses of Carnitin

What Carnitine Treats: Main Uses and Benefits

Carnitine may be used to help manage symptoms associated with carnitine deficiency, including both primary and secondary forms. It is applied across domains where additional symptomatic support is needed in contexts involving heightened systemic burden. Carnitine may be considered relevant for easing symptom clusters that may become intense or disruptive.

Therapeutic Focus Areas

Therapeutic domains for carnitine may include offering supportive comfort in cardiovascular symptom management, easing symptom burden in neuropathic distress and fatigue, and assistance in symptom stabilization during metabolic challenges. It is commonly used across conditions presenting with acute or disruptive episodes where symptoms escalate temporarily. This use provides support that helps ease the overall symptom load and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Symptomatic Support for Muscle Weakness

Carnitine may be relevant during phases when symptoms become more noticeable, commonly used to address muscle weakness and poor muscle tone associated with carnitine deficiency.

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Carnitin (Levocarnitine)

Carnitin is officially indicated for patients diagnosed with primary systemic carnitine deficiency or secondary carnitine deficiency resulting from inborn errors of metabolism. Use is established across all age groups, including infants, children, and adults, for these approved deficiency states.


Contraindications and Conditional Use

While the active ingredient itself has no absolute contraindications listed in U.S. regulatory labeling, use is subject to strict population restrictions and required caution. Specific oral formulations are contraindicated in patients with hereditary fructose intolerance due to excipient content, and in patients with known hypersensitivity to the drug.

  • Renal Impairment: The chronic administration of high doses of oral levocarnitine is not recommended for patients with severely compromised renal function or those undergoing dialysis.
  • Seizure History: The medicine must be used with caution in patients with a pre-existing history of seizure activity, as an increase in seizure frequency has been reported.
  • Pregnancy and Lactation: Use during pregnancy is conditional and permitted only if clearly needed. For nursing mothers, treatment requires regulatory evaluation to weigh the risks versus the benefits.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for Levocarnitine focuses on medicines that influence the body’s internal carnitine balance, as documented in regulatory sources.

Interactions that Affect Carnitine Exposure

The co-administration of Levocarnitine with Valproic Acid is formally associated with increased renal excretion of carnitine, as noted in prescribing information. This process is recorded as potentially reducing the body's overall carnitine exposure. Furthermore, pivalate-containing antibiotics, such as Pivampicillin, promote carnitine loss through the formation and elimination of carnitine conjugates, which is documented as resulting in a reduction in carnitine plasma concentration.

Pharmacodynamic and Administration Constraints

An important interaction observation involves Vitamin K Antagonists. Co-administration of Levocarnitine with agents like Warfarin or Acenocoumarol has been associated with an increase in International Normalized Ratio (INR), suggesting a potential pharmacodynamic reinforcement of the anticoagulant effect, as noted in post-marketing data. The official label for oral Levocarnitine formulations requires the medicine to be administered with meals as a mandatory condition to optimize drug absorption.

Population-Specific Note

Regulatory documentation highlights a caution for patients with severe renal impairment (including those on dialysis). Chronic administration of high-dose oral Levocarnitine in this group is associated with the accumulation of metabolites, such as trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), which are normally cleared by the kidneys.

Mechanism of Action

Facilitating Energy Substrate Utilization through Fatty Acid Transport

The primary mechanism of Carnitine involves facilitating the transport of long-chain fatty acids into the cell's energy-producing compartments, the mitochondria. Carnitine acts as an essential cofactor within the Carnitine Shuttle system. This system utilizes the Carnitine Palmitoyltransferase (CPT) enzymes to enable fatty acids to traverse the inner mitochondrial membrane, thereby providing the substrate for the beta-oxidation pathway. This action dictates the flux of fatty acids into the pathway and contributes to the regulation of cellular ATP (energy) synthesis.


Modulating Acyl-CoA Ratios and Metabolite Homeostasis

A second mechanistic function of Carnitine is the management of acyl-CoA compounds via metabolic buffering. This mechanism involves the enzyme Carnitine O-acetyltransferase (CAT), which binds excess long-chain acyl-CoA compounds. This action converts them into acylcarnitines, which are subsequently removed from the mitochondria. This assists in the modification of these acyl-CoA compounds and their removal, which influences downstream metabolic activity and the maintenance of proper metabolic flux within the cell.

Dosage and Administration Information

Administration Instructions for Carnitin (Levocarnitine)

Administration of levocarnitine involves specific procedural rules for both oral and intravenous (IV) formulations. It is important not to change between different brands or dosage forms (e.g., solution to tablet) without consulting a healthcare provider, as product performance may vary.

Dosing and Administration

Route of Administration Dosing Rules (Adults) Timing and Frequency
Oral Tablet Initial: 990 mg two to three times per day. Max: 3 g/ day. Take with or just after meals. Doses should be spaced evenly throughout the day.
Oral Solution Initial: 1 g once daily. Max: 3 g/ day in divided doses. Take with or just after meals. Doses should be spaced evenly (every 3 to 4 hours minimum).
Intravenous (IV) Initial: 50 mg/ kg as a slow 2 to 3 minute bolus. Administered daily, or every 3 to 6 hours in severe metabolic crisis.

Procedural and Age-Specific Rules

  • Children and Infants: Both oral and IV doses are calculated based on body weight, typically starting at 50 mg/ kg/ day in divided doses, and must be determined by a healthcare professional. Oral doses should be given with or after feedings.
  • Hemodialysis Patients (IV): A starting dose of 10 to 20 mg/ kg is administered into the venous return line after each dialysis session.
  • Preparation: The oral solution may be consumed alone or dissolved in other liquid foods or drinks to improve tolerance. It must be consumed slowly to help maximize tolerance and minimize potential gastrointestinal upset.
  • Missed Dose: If a dose is missed, take it as soon as possible. If it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Do not take double doses.

Recent Clinical Evidence

Carnitin: Recent Clinical Evidence


Evidence for Carnitin as Replacement Therapy in Deficiency States

The primary research for Levocarnitine is structured around its evaluation in contexts involving metabolic imbalances where a carnitine deficiency is present. This use is based on interventional studies and long-term observational cohorts that monitored biomarkers, primarily the restoration of carnitine levels in plasma and tissues, in infants, children, and adults. Research limitations include small patient cohorts due to the rarity of the conditions, meaning comprehensive long-term functional outcomes are not fully characterized.


Evidence for Symptomatic Support in Kidney Disease and Dialysis

Levocarnitine has been studied in patients with End-Stage Renal Disease (ESRD) receiving maintenance hemodialysis. The research relies on Randomized Controlled Trials (RCTs) and meta-analyses, examining symptomatic outcomes such as muscle cramps and blood pressure measurements. Findings were mixed across studies for certain clinical endpoints, and significant heterogeneity exists across the RCTs. Follow-up durations were often limited to intermediate-term observation (e.g., 3 to 6 months).


Research on Supportive Use for Fatigue and Systemic Symptoms

Levocarnitine was evaluated in placebo-controlled trials exploring patient-reported experiences related to fatigue in chronic systemic conditions like Multiple Sclerosis and HIV/AIDS. Studies monitored subjective changes using validated fatigue scales. However, research describes that findings were mixed across different chronic diseases and dependent on the specific assessment tool used. The evidence is generally characterized as inconsistent, and studies often explored short-term symptom changes only.


Key Research Gaps and Uncertainties

Primary research limitations documented in the literature include that sample sizes were modest in studies of rare diseases. Evidence quality varies across studies, with significant heterogeneity noted across trials for symptomatic relief. Subgroup findings are uncertain, and long-term effects are not fully established across all indications.

Frequently Asked Questions (FAQ)

Common questions about Carnitin (FAQ)


Q: Are there any serious but rare side effects associated with Carnitin use?

Official documents describe certain serious reactions, although they are uncommon. These include severe allergic responses, such as anaphylaxis or swelling of the voice box (laryngeal edema), reported primarily with the intravenous form.

Regulatory warnings also mention an increase in seizure frequency or severity in patients who already have a history of seizure activity.


Q: Can Carnitin be taken at the same time as my other regular medications?

Official product information focuses on known, specific interactions with certain other medicines. For example, regulatory documents detail interactions with Valproic Acid (an anti-seizure medicine) and Vitamin K Antagonists (blood thinners like Warfarin).

If a patient is taking multiple prescription or non-prescription medicines, official guidance suggests confirming potential conflicts, as the product label does not contain a blanket statement covering all possible drugs.


Q: Are there any vitamins or supplements that are known to interact with Carnitin?

Regulatory sources primarily detail known interactions with other prescription medications, such as certain antibiotics and blood thinners.

Official information does not typically list interactions with common vitamins. General guidance from official sources suggests reviewing all supplements and vitamins being taken to avoid unintended effects.


Q: What is the relationship between Carnitin and thyroid hormones?

Official research themes indicate that studies have examined the potential connection between L-carnitine and thyroid hormone activity.

Some research has explored its use in people with an underactive thyroid (hypothyroidism) who also experience fatigue.


Q: Does Carnitin therapy require regular blood tests or monitoring?

Official documentation mentions certain patient monitoring requirements in specific contexts. For example, the International Normalized Ratio (INR) may need monitoring when Carnitin is used with certain blood-thinning medicines.

Monitoring plasma carnitine concentrations is also described in official treatment guides as a way to track therapeutic effect.


Q: Can Carnitin be taken with or without food?

Official labeling states the medicine is typically administered with or just after meals for oral formulations (solution and tablets).

This condition is in place to help maximize the absorption of the drug into the body.


Q: Is it true that Carnitin can affect the risk of seizures in certain patients?

Yes, official regulatory warnings state that the medicine must be used with caution in individuals who have a pre-existing history of seizure activity.

Reports in official documents indicate that an increase in seizure frequency and/or severity has been noted in this patient group.


Q: Are there different forms of Carnitin, such as tablet versus liquid?

The drug is officially supplied in several pharmaceutical forms, including a solution for injection (intravenous use), an oral solution, and tablets.

All forms contain the active ingredient Levocarnitine (L-carnitine), which is the only biologically active form of the compound needed by the body.


Q: What is the general difference in purpose between L-Carnitine and Acetyl-L-Carnitine?

L-Carnitine is the active substance used in prescription Carnitin therapy, focused on restoring the body's primary metabolic 'shuttle' function.

NIH-linked information describes Acetyl-L-Carnitine (ALCAR) as a related chemical form that has been studied for different suggested purposes, such as effects involving the nervous system.


Q: Is there a concern about Carnitin raising levels of a compound called TMAO?

Regulatory warnings highlight that chronic use of high-dose oral Carnitin in patients with severely compromised kidney function, including those on dialysis, is associated with the accumulation of metabolites.

These metabolites include trimethylamine (TMA) and trimethylamine-N-oxide (TMAO).


Q: Does the liquid version of Carnitin need to be diluted or taken straight?

Official procedural rules state that the oral solution may be consumed alone. However, rules also allow it to be dissolved in other liquid foods or drinks.

This flexibility is provided to help improve tolerance and minimize the potential for gastrointestinal upset, as noted in procedural rules.


Q: If I experience a headache while on Carnitin, is that a common side effect?

Official regulatory lists of side effects reported in clinical trials and post-marketing data include headache.

While gastrointestinal symptoms are generally described as more common, headache is included in the list of less common adverse reactions.


Q: Does the prescription brand of Carnitin contain the D,L-carnitine form?

No. Official drug information explicitly states that the active ingredient is Levocarnitine (L-carnitine).

Regulatory documentation highlights that the inactive D-carnitine isomer is chemically distinct and can interfere with the essential L-form's action, which is why prescription products use the pure L-form.


Q: How effective is the body's absorption of carnitine from supplements compared to food?

Research documentation shows a difference in how the body absorbs carnitine based on the source. The bioavailability (the amount absorbed) of L-carnitine from food is generally higher.

In contrast, studies indicate that the absorption of L-carnitine from high-dose oral supplements is typically much lower.


Q: Is it necessary to take Carnitin more than once a day to maintain constant blood levels?

Official administration advice specifies that if a patient takes multiple doses per day, those doses should be taken at evenly spaced times.

This is done to help keep a constant amount of the medicine in the blood, which regulatory information states makes the medicine less likely to cause unwanted effects.


How should Carnitin be stored and disposed of?

How to Store and Dispose of Carnitin?

This information details the officially documented storage and disposal requirements for Carnitin (Levocarnitine), based strictly on regulatory labeling.

Requirement Category Official Storage/Stability Rules
Temperature & Protection Store at Controlled Room Temperature (20^circ to 25 C); protect the product from freezing, excessive heat, and light.
Container & Stability Vials must be retained in the outer carton; discard the unused portion of an opened single-dose vial immediately. The oral solution must be discarded 30 to 60 days after first opening.
Safety & Disposal Keep out of the reach of children and pets. Dispose of any unused or expired product in accordance with local requirements; do not dispose of via wastewater unless specifically instructed.

These protocols ensure the product's integrity and adherence to official environmental and safety mandates.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carnitin found in:

A-Z Index: